Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JH, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP.

JAMA Oncol. 2019 Sep 5. doi: 10.1001/jamaoncol.2019.2792. [Epub ahead of print]

PMID:
31486832
2.

Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules.

Mokrane FZ, Lu L, Vavasseur A, Otal P, Peron JM, Luk L, Yang H, Ammari S, Saenger Y, Rousseau H, Zhao B, Schwartz LH, Dercle L.

Eur Radiol. 2019 Aug 23. doi: 10.1007/s00330-019-06347-w. [Epub ahead of print]

PMID:
31444598
3.

Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence.

Sinigaglia M, Assi T, Besson FL, Ammari S, Edjlali M, Feltus W, Rozenblum-Beddok L, Zhao B, Schwartz LH, Mokrane FZ, Dercle L.

EJNMMI Res. 2019 Aug 20;9(1):78. doi: 10.1186/s13550-019-0542-5. Review.

4.

Automatic liver segmentation by integrating fully convolutional networks into active contour models.

Guo X, Schwartz LH, Zhao B.

Med Phys. 2019 Jul 29. doi: 10.1002/mp.13735. [Epub ahead of print]

PMID:
31356688
5.

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.

Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, Moya-Plana A, Mokrane FZ, Gartrell RD, Finkel G, Barker L, Bigorgne AE, Schwartz LH, Saenger Y, Robert C, Dercle L.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2298-2310. doi: 10.1007/s00259-019-04411-7. Epub 2019 Jul 25.

PMID:
31346755
6.

Nonenhancing Component of Clear Cell Renal Cell Carcinoma on Computed Tomography Correlates With Tumor Necrosis and Stage and Serves as a Size-Independent Prognostic Biomarker.

Ahmed FS, Akin O, Shaish H, Luk L, Guo X, Yang H, Zabor E, Ostrovnaya I, Hakimi AA, Zhao B, Schwartz LH.

J Comput Assist Tomogr. 2019 Jul/Aug;43(4):628-633. doi: 10.1097/RCT.0000000000000877.

PMID:
31162237
7.

Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks.

Ma J, Dercle L, Lichtenstein P, Wang D, Chen A, Zhu J, Piessevaux H, Zhao J, Schwartz LH, Lu L, Zhao B.

Acad Radiol. 2019 May 28. pii: S1076-6332(19)30171-0. doi: 10.1016/j.acra.2019.02.024. [Epub ahead of print]

PMID:
31151901
8.

Eye Tracking for Deep Learning Segmentation Using Convolutional Neural Networks.

Stember JN, Celik H, Krupinski E, Chang PD, Mutasa S, Wood BJ, Lignelli A, Moonis G, Schwartz LH, Jambawalikar S, Bagci U.

J Digit Imaging. 2019 Aug;32(4):597-604. doi: 10.1007/s10278-019-00220-4.

9.

The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI.

Rozenblum L, Mokrane FZ, Yeh R, Sinigaglia M, Besson F, Seban RD, Chougnet CN, Revel-Mouroz P, Zhao B, Otal P, Schwartz LH, Dercle L.

Abdom Radiol (NY). 2019 Jul;44(7):2474-2493. doi: 10.1007/s00261-019-01994-5. Review.

PMID:
30980115
10.

CT-Based Radiomics Model for Predicting Brain Metastasis in Category T1 Lung Adenocarcinoma.

Chen A, Lu L, Pu X, Yu T, Yang H, Schwartz LH, Zhao B.

AJR Am J Roentgenol. 2019 Apr 1:1-6. doi: 10.2214/AJR.18.20591. [Epub ahead of print]

PMID:
30933649
11.

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.

Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, Therasse P, Seymour L; RECIST Working Group.

J Clin Oncol. 2019 May 1;37(13):1102-1110. doi: 10.1200/JCO.18.01100. Epub 2019 Mar 12.

PMID:
30860949
12.

Reliability of Radiomic Features Across Multiple Abdominal CT Image Acquisition Settings: A Pilot Study Using ACR CT Phantom.

Lu L, Liang Y, Schwartz LH, Zhao B.

Tomography. 2019 Mar;5(1):226-231. doi: 10.18383/j.tom.2019.00005.

13.

A Web-Based Response-Assessment System for Development and Validation of Imaging Biomarkers in Oncology.

Yang H, Guo X, Schwartz LH, Zhao B.

Tomography. 2019 Mar;5(1):220-225. doi: 10.18383/j.tom.2019.00006.

14.

Multicenter Repeatability Study of a Novel Quantitative Diffusion Kurtosis Imaging Phantom.

Malyarenko DI, Swanson SD, Konar AS, LoCastro E, Paudyal R, Liu MZ, Jambawalikar SR, Schwartz LH, Shukla-Dave A, Chenevert TL.

Tomography. 2019 Mar;5(1):36-43. doi: 10.18383/j.tom.2018.00030.

15.

Repeatability of Quantitative Diffusion-Weighted Imaging Metrics in Phantoms, Head-and-Neck and Thyroid Cancers: Preliminary Findings.

Paudyal R, Konar AS, Obuchowski NA, Hatzoglou V, Chenevert TL, Malyarenko DI, Swanson SD, LoCastro E, Jambawalikar S, Liu MZ, Schwartz LH, Tuttle RM, Lee N, Shukla-Dave A.

Tomography. 2019 Mar;5(1):15-25. doi: 10.18383/j.tom.2018.00044.

16.

Artificial intelligence in cancer imaging: Clinical challenges and applications.

Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, Mak RH, Tamimi RM, Tempany CM, Swanton C, Hoffmann U, Schwartz LH, Gillies RJ, Huang RY, Aerts HJWL.

CA Cancer J Clin. 2019 Mar;69(2):127-157. doi: 10.3322/caac.21552. Epub 2019 Feb 5. Review.

17.

Radiomics for Classifying Histological Subtypes of Lung Cancer Based on Multiphasic Contrast-Enhanced Computed Tomography.

E L, Lu L, Li L, Yang H, Schwartz LH, Zhao B.

J Comput Assist Tomogr. 2019 Mar/Apr;43(2):300-306. doi: 10.1097/RCT.0000000000000836.

PMID:
30664116
18.

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

Dercle L, Connors DE, Tang Y, Adam SJ, Gönen M, Hilden P, Karovic S, Maitland M, Moskowitz CS, Kelloff G, Zhao B, Oxnard GR, Schwartz LH.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.17.00137.

19.

Sorafenib for Advanced and Refractory Desmoid Tumors.

Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK.

N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052.

20.

CT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary Study.

Li Y, Lu L, Xiao M, Dercle L, Huang Y, Zhang Z, Schwartz LH, Li D, Zhao B.

Sci Rep. 2018 Dec 17;8(1):17913. doi: 10.1038/s41598-018-36421-0.

21.

Radiomics for Classification of Lung Cancer Histological Subtypes Based on Nonenhanced Computed Tomography.

E L, Lu L, Li L, Yang H, Schwartz LH, Zhao B.

Acad Radiol. 2019 Sep;26(9):1245-1252. doi: 10.1016/j.acra.2018.10.013. Epub 2018 Nov 28.

PMID:
30502076
22.

Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials.

Shukla-Dave A, Obuchowski NA, Chenevert TL, Jambawalikar S, Schwartz LH, Malyarenko D, Huang W, Noworolski SM, Young RJ, Shiroishi MS, Kim H, Coolens C, Laue H, Chung C, Rosen M, Boss M, Jackson EF.

J Magn Reson Imaging. 2019 Jun;49(7):e101-e121. doi: 10.1002/jmri.26518. Epub 2018 Nov 19. Review.

PMID:
30451345
23.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
24.

Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.

Kaufman HL, Schwartz LH, William WN Jr, Sznol M, Fahrbach K, Xu Y, Masson E, Vergara-Silva A.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2245-2261. doi: 10.1007/s00432-018-2738-x. Epub 2018 Aug 21. Review.

PMID:
30132118
25.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS.

J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.

26.

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1219-1235. doi: 10.1016/j.ijrobp.2018.06.023. Epub 2018 Jun 30. Review.

27.

Artificial intelligence in radiology.

Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL.

Nat Rev Cancer. 2018 Aug;18(8):500-510. doi: 10.1038/s41568-018-0016-5. Review.

28.

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.

Claret L, Pentafragka C, Karovic S, Zhao B, Schwartz LH, Maitland ML, Bruno R.

Cancer Chemother Pharmacol. 2018 Jul;82(1):49-54. doi: 10.1007/s00280-018-3587-7. Epub 2018 Apr 26.

PMID:
29700575
29.

Lymph node segmentation by dynamic programming and active contours.

Tan Y, Lu L, Bonde A, Wang D, Qi J, Schwartz LH, Zhao B.

Med Phys. 2018 May;45(5):2054-2062. doi: 10.1002/mp.12844. Epub 2018 Apr 1.

PMID:
29500866
30.

Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

Dercle L, Ammari S, Seban RD, Schwartz LH, Houot R, Labaied N, Mokrane FZ, Lazarovici J, Danu A, Marabelle A, Ribrag V, Michot JM.

Eur J Cancer. 2018 Mar;91:136-144. doi: 10.1016/j.ejca.2017.12.015.

PMID:
29360605
31.

Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm.

Dercle L, Lu L, Lichtenstein P, Yang H, Wang D, Zhu J, Wu F, Piessevaux H, Schwartz LH, Zhao B.

JCO Clin Cancer Inform. 2017 Nov;1:1-8. doi: 10.1200/CCI.17.00108.

32.

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.

Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E; Alliance for Clinical Trials on Oncology.

BMC Cancer. 2017 Jul 27;17(1):505. doi: 10.1186/s12885-017-3441-z.

33.

18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor.

Dercle L, Seban RD, Lazarovici J, Schwartz LH, Houot R, Ammari S, Danu A, Edeline V, Marabelle A, Ribrag V, Michot JM.

J Nucl Med. 2018 Jan;59(1):15-24. doi: 10.2967/jnumed.117.193011. Epub 2017 Jun 8.

34.

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL.

Neuro Oncol. 2017 Nov 29;19(12):1688-1697. doi: 10.1093/neuonc/nox092.

35.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

36.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group.

Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

37.

A Multiparametric Model for Mapping Cellularity in Glioblastoma Using Radiographically Localized Biopsies.

Chang PD, Malone HR, Bowden SG, Chow DS, Gill BJA, Ung TH, Samanamud J, Englander ZK, Sonabend AM, Sheth SA, McKhann GM 2nd, Sisti MB, Schwartz LH, Lignelli A, Grinband J, Bruce JN, Canoll P.

AJNR Am J Neuroradiol. 2017 May;38(5):890-898. doi: 10.3174/ajnr.A5112. Epub 2017 Mar 2.

38.

Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2017 Feb 17;7:41197. doi: 10.1038/srep41197. No abstract available.

39.

Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al.

Brown KT, Do R, Gönen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson K, Garcia AR, Beattie CM, Zhao B, Solomon SB, Schwartz LH, DeMatteo RP, Abou-Alfa GK.

J Clin Oncol. 2017 Jan 10;35(2):258-259. Epub 2016 Oct 23. No abstract available.

PMID:
28056199
40.

Assessing Agreement between Radiomic Features Computed for Multiple CT Imaging Settings.

Lu L, Ehmke RC, Schwartz LH, Zhao B.

PLoS One. 2016 Dec 29;11(12):e0166550. doi: 10.1371/journal.pone.0166550. eCollection 2016.

41.

Volumetry of low-contrast liver lesions with CT: Investigation of estimation uncertainties in a phantom study.

Li Q, Liang Y, Huang Q, Zong M, Berman B, Gavrielides MA, Schwartz LH, Zhao B, Petrick N.

Med Phys. 2016 Dec;43(12):6608.

42.

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.

Falchi L, Sawas A, Deng C, Amengual JE, Colbourn DS, Lichtenstein EA, Khan KA, Schwartz LH, O'Connor OA.

J Hematol Oncol. 2016 Nov 30;9(1):132.

43.

A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology.

Yang H, Schwartz LH, Zhao B.

Tomography. 2016 Dec;2(4):406-410. doi: 10.18383/j.tom.2016.00223.

44.

Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.

Giesel FL, Schneider F, Kratochwil C, Rath D, Moltz J, Holland-Letz T, Kauczor HU, Schwartz LH, Haberkorn U, Flechsig P.

J Nucl Med. 2017 Feb;58(2):282-287. doi: 10.2967/jnumed.116.179648. Epub 2016 Sep 22.

45.

Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2016 Sep 20;6:33860. doi: 10.1038/srep33860. Erratum in: Sci Rep. 2017 Feb 17;7:41197.

46.

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.

Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH.

J Clin Oncol. 2016 Oct 20;34(30):3680-3685. doi: 10.1200/JCO.2016.68.1858.

47.

Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients.

Flechsig P, Frank P, Kratochwil C, Antoch G, Rath D, Moltz J, Rieser M, Warth A, Kauczor HU, Schwartz LH, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2017 Apr;19(2):315-322. doi: 10.1007/s11307-016-0996-z.

PMID:
27539308
48.

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E.

Eur J Cancer. 2016 Jul;62:138-45. doi: 10.1016/j.ejca.2016.03.082. Epub 2016 May 26. Review.

49.

RECIST 1.1-Update and clarification: From the RECIST committee.

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L.

Eur J Cancer. 2016 Jul;62:132-7. doi: 10.1016/j.ejca.2016.03.081. Epub 2016 May 14.

50.

Reproducibility of radiomics for deciphering tumor phenotype with imaging.

Zhao B, Tan Y, Tsai WY, Qi J, Xie C, Lu L, Schwartz LH.

Sci Rep. 2016 Mar 24;6:23428. doi: 10.1038/srep23428.

Supplemental Content

Loading ...
Support Center